Dasanix 50 mg (Tablet)

Unit Price: ৳ 200.00 (6 x 10: ৳ 12,000.00)
Strip Price: ৳ 2,000.00

Medicine Details

Category Details
Generic Dasatinib
Company Beacon pharmaceuticals plc
Also available as
Dasanix 20 mg tablet Dasanix 100 mg tablet

Indications

  • Treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
  • Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
  • Treatment of newly diagnosed Ph+ acute lymphoblastic leukemia (ALL)
  • Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy

Pharmacology

  • Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
  • Modeling studies predicting binding to multiple conformations of the ABL kinase
  • Activity in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
  • Inhibition of CML and ALL cell lines overexpressing BCR-ABL
  • Prediction of overcoming imatinib resistance and multi-drug resistance gene overexpression

Absorption

Cmax observed between 0.5 to 6 hours, increased AUC with high-fat meal

Distribution

  • Apparent volume of distribution: 2505 (CV% 93%)
  • Binding of Dasatinib to human plasma proteins: approximately 96%
  • P-gp substrate in vitro

Elimination

  • Mean terminal half-life: 3 to 5 hours
  • Apparent oral clearance: 363.8 l/hr (CV% 81.3%)
  • Primary metabolism by CYP3A4
  • Excretion primarily via feces

Dosage & Administration

  • Recommended starting dosage: 100 mg once daily for chronic phase CML in adults, 140 mg once daily for accelerated phase CML or Ph+ ALL in adults
  • Recommended starting dosages for pediatric patients based on body weight
  • Tablets should not be crushed, cut, or chewed, and can be taken with or without a meal

Interaction

  • Strong CYP3A4 inhibitors may increase Dasanix concentrations
  • Strong CYP3A4 inducers may decrease Dasanix concentrations
  • Coadministration with gastric acid reducing agents may decrease Dasanix concentrations

Contraindications

Known hypersensitivity to Dasatinib or any component of the formulation

Side Effects

  • Myelosuppression
  • Bleeding-related events
  • Fluid retention
  • Cardiovascular events
  • Pulmonary arterial hypertension
  • QT prolongation
  • Severe dermatologic reactions
  • Tumor lysis syndrome
  • Effects on growth and development in pediatric patients

Pregnancy & Lactation

Potential fetal harm, effective contraceptive methods advised for females of reproductive potential, breastfeeding not recommended

Precautions & Warnings

  • Severe (NCT CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia
  • Bleeding-related events
  • Fluid retention
  • Cardiovascular events
  • Pulmonary arterial hypertension
  • QT prolongation
  • Severe dermatologic reactions
  • Tumor lysis syndrome

Overdose Effects

Experience limited to isolated cases, severe myelosuppression and bleeding reported

Therapeutic Class

Targeted Cancer Therapy

Storage Conditions

Store below 30°C in a dry place, protect from light, keep out of reach of children

Related Brands